pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wave Life Sciences Ltd. ($WVE) · news · pharmadog
← back to Wave Life Sciences Ltd.
News mentioning $WVE
14
stories
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
6d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
9d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
Oct 13, 26
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
Oct 8, 26
Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARM
biospace
Oct 1, 26
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
Sep 30, 26
GSK continues to stock up on Wave's RNA drugs with liver-focused program
fiercebiotech
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 24, 26
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
Sep 8, 26
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
Aug 6, 26
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
Aug 5, 26
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
May 19, 26
Wave aims for monthly dosing with RNA editing treatment for AATD
endpoints